AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22926853 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (33,000 IU intravenously daily for 3 days)
Number of subjects: 40
Study 22926853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (as an add-on therapy to methylprednisolone)
Number of subjects: 40
Study 22926853 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 40
Study 20730705 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 34
Study 20730705 — intervention group
Group type: COMPARATOR
Intervention: Diane (35) Diario contraceptive pill (35 μg of ethynylestradiol plus 2 mg of cyproterone acetate)
Number of subjects: 34
Study 20730705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 34
Study 17393448 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 degrees lateral-wedge insole
Number of subjects: 90
Study 17393448 — intervention group
Group type: COMPARATOR
Intervention: Neutral insole
Number of subjects: 90
Study 16112085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel treatment in patients with valine homozygotic genotype
Number of subjects: 111
Study 16112085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel treatment in patients with G allele
Number of subjects: 111
Study 11961333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride chewing gums
Number of subjects: 15
Study 11961333 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea chewing gums
Number of subjects: 15
Study 11961333 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gums
Number of subjects: 15
Study 11961333 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 15
Study 10331327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediapred (Medeva Pharmaceuticals, Rochester, NY)
Number of subjects: 0
Study 10331327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelone (Muro Pharmaceuticals, Tewksbury, MA)
Number of subjects: 0
Study 10331327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone oral solution
Number of subjects: 0
Study 10331327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone intensol
Number of subjects: 0
Study 10331327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 10‐mg tablet crushed in 10 mL of cherry syrup
Number of subjects: 0
Study 10331327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison of each formulation
Number of subjects: 0
Study 9112163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 20 microliters of 0.5% timolol solution
Number of subjects: 17
Study 9112163 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ocular administration of 20 microliters of 0.5% timolol solution
Number of subjects: 17
Study 9112163 — intervention group
Group type: COMPARATOR
Intervention: Sublingual administration of 20 microliters of saline solution (placebo)
Number of subjects: 17
Study 9112163 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ocular administration of 20 microliters of saline solution (placebo)
Number of subjects: 17
Study 1745711 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g sugar with alcohol
Number of subjects: 0
Study 1745711 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g sugar with alcohol
Number of subjects: 0
Study 1745711 — intervention group
Group type: COMPARATOR
Intervention: 0 g sugar with alcohol
Number of subjects: 0
Study 1745711 — intervention group
Group type: COMPARATOR
Intervention: Sugar without alcohol
Number of subjects: 0
Study 6351607 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents
Number of subjects: 102
Study 6351607 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids alone
Number of subjects: 102
Study 6351607 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity and chronicity indexes
Number of subjects: 102
Study 6351607 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and chronicity index
Number of subjects: 102
Study 31500679 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (100 µg)
Number of subjects: 25
Study 31500679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg) pretreatment with LSD
Number of subjects: 25
Study 31500679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29411727 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft + T-PRF
Number of subjects: 25
Study 29411727 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 25
Study 27005405 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Number of subjects: 359
Study 25263254 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX-A 25U
Number of subjects: 84
Study 25263254 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX-A 75U
Number of subjects: 84
Study 25263254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 23006613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU monthly)
Number of subjects: 50
Study 23006613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 50
Study 23006613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20354522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic cyclophosphamide (50 mg b.i.d)
Number of subjects: 88
Study 20354522 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (160 mg daily)
Number of subjects: 88
Study 18033974 — intervention group
Group type: EXPERIMENTAL
Intervention: Various tonsillectomy techniques (9 different techniques)
Number of subjects: 44
Study 18033974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for future studies
Number of subjects: 44
Study 15708051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (SC)
Number of subjects: 60
Study 15708051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12486342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single BAK fusion cage inserted posterolaterally with unilateral facetectomy and hemilaminectomy (Group 1)
Number of subjects: 25
Study 12486342 — intervention group
Group type: COMPARATOR
Intervention: Two BAK fusion cages inserted posteriorly with bilateral facetectomy and laminectomy (Group 2)
Number of subjects: 25
Study 10213254 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar macrophages (AM) from children with recurrent infections
Number of subjects: 0
Study 10213254 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (children without recurrent infections)
Number of subjects: 0
Study 7606951 — intervention group
Group type: EXPERIMENTAL
Intervention: DeVilbiss Pulmo‐Aide compressor with the Marquest Acorn II nebulizer
Number of subjects: 397
Study 7606951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson T Up‐draft nebulizer
Number of subjects: 397
Study 7606951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari LC Jet Plus nebulizer with the Pari Inhalier Boy compressor
Number of subjects: 397
Study 2193071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 30
Study 2193071 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study 42487 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (multiple doses)
Number of subjects: 2
Study 42487 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (twice-daily schedule)
Number of subjects: 2
Study 42487 — intervention group
Group type: COMPARATOR
Intervention: Timolol (single oral doses)
Number of subjects: 2
Study 31771436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol (1:3) - low-dose ketamine 0.15 mg/kg followed by propofol 0.45 mg/kg i.v.
Number of subjects: 120
Study 31771436 — intervention group
Group type: COMPARATOR
Intervention: Control - normal saline and dextrose
Number of subjects: 120
Study 30623905 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal education based on the Roy Adaptation Model
Number of subjects: 132
Study 30623905 — intervention group
Group type: COMPARATOR
Intervention: Control group (due medical care alone)
Number of subjects: 132
Study 27704286 — intervention group
Group type: EXPERIMENTAL
Intervention: Herniectomy and DIAM spinal stabilization system
Number of subjects: 146
Study 27704286 — intervention group
Group type: COMPARATOR
Intervention: Herniectomy alone
Number of subjects: 146
Study 26215946 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% aqueous lidocaine
Number of subjects: 46
Study 26215946 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% aqueous lidocaine (after open-label use)
Number of subjects: 46
Study 26215946 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 46
Study 23371895 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA loading dose of 50 mg/kg over 15 min followed by a 5 mg/kg/h maintenance infusion during surgery
Number of subjects: 23
Study 23371895 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated loading dose of 10 mg/kg over 15 min followed by a 5 mg/kg/h maintenance infusion
Number of subjects: 23
Study 21080787 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) with anorganic bone mineral/peptide‐15 (ABM/P‐15)
Number of subjects: 15
Study 21080787 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap (CPF) only
Number of subjects: 15
Study 19198007 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete embolic protection
Number of subjects: 44
Study 19198007 — intervention group
Group type: COMPARATOR
Intervention: Partial embolic protection
Number of subjects: 44
Study 19198007 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 44
Study 19198007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19198007 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab in partial protection group
Number of subjects: 44
Study 19198007 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab in complete protection group
Number of subjects: 44
Study 19198007 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete protection
Number of subjects: 44
Study 17889127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CyA)
Number of subjects: 81
Study 17889127 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TC)
Number of subjects: 81
Study 15365919 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone, 5 microg/kg/min (group A)
Number of subjects: 216
Study 15365919 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine at the same dose (group B)
Number of subjects: 216
Study 11515819 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-CWS stimulation
Number of subjects: 0
Study 11515819 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-tumor resection
Number of subjects: 0
Study 9755346 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Training (PST)
Number of subjects: 341
Study 9755346 — intervention group
Group type: COMPARATOR
Intervention: General Health Counseling (GHC)
Number of subjects: 341
Study 9122547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact milk
Number of subjects: 25
Study 9122547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk (> 90% of lactose hydrolyzed)
Number of subjects: 25
Study 9122547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk
Number of subjects: 25
Study 2184179 — intervention group
Group type: EXPERIMENTAL
Intervention: Re‐PUVA
Number of subjects: 20
Study 2184179 — intervention group
Group type: EXPERIMENTAL
Intervention: Re
Number of subjects: 20
Study 2184179 — intervention group
Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 20
Study 7268333 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk‐Shiley (B‐S) valves
Number of subjects: 300
Study 7268333 — intervention group
Group type: COMPARATOR
Intervention: Lillehei‐Kaster (L‐K) valves
Number of subjects: 300
Study 29726739 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg ixekizumab every 2 weeks (IXEQ2W)
Number of subjects: 0
Study 29726739 — intervention group
Group type: COMPARATOR
Intervention: 50 mg etanercept (ETN) biweekly
Number of subjects: 0
Study 29726739 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg ixekizumab every 4 weeks (IXEQ4W)
Number of subjects: 0
Study 28644370 — intervention group
Group type: EXPERIMENTAL
Intervention: New Complementary Feeding Guidelines (NCFg) focusing on meat, fruits, vegetables, and breast milk
Number of subjects: 72
Study 28644370 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative food-based recommendations (FBRs) promoting legumes, dairy, vitamin A-rich vegetables, and chicken giblets
Number of subjects: 72
Study 28644370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified infant food
Number of subjects: 72
Study 26404200 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR (TF-TAVR)
Number of subjects: 3013
Study 26404200 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical TAVR (TA-TAVR)
Number of subjects: 3013
Study 25066921 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 210
Study 25066921 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 210
Study 25066921 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 210
Study 22690320 — intervention group
Group type: EXPERIMENTAL
Intervention: WGOE supplementation (1500 mg/day)
Number of subjects: 37
Study 22690320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 19304577 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose larvae
Number of subjects: 267
Study 19304577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bagged larvae
Number of subjects: 267
Study 19304577 — intervention group
Group type: COMPARATOR
Intervention: Larval therapy (loose or bagged larvae)
Number of subjects: 267
Study 19304577 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 267
Study 17692126 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg)
Number of subjects: 84
Study 17692126 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Number of subjects: 84
Study 17692126 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 84
Study 17692126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 15558649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dissonance‐based, thin‐ideal internalization, single‐session workshop (DTI; n = 26)
Number of subjects: 84
Study 15558649 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational, healthy behavior, single‐session workshop (HB; n = 24)
Number of subjects: 84
Study 15558649 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL; n = 34)
Number of subjects: 84
Study 11280847 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of zidovudine (AZT)
Number of subjects: 0
Study 11280847 — intervention group
Group type: COMPARATOR
Intervention: High dose of zidovudine (AZT)
Number of subjects: 0
Study 9004877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 100
Study 9004877 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTon
Number of subjects: 100
Study 9004877 — intervention group
Group type: COMPARATOR
Intervention: HAT (Hand-held Applanation Tonometer)
Number of subjects: 100
Study 9004877 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 100
Study 9004877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen I vs II
Number of subjects: 100
Study 9004877 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTon I vs II
Number of subjects: 100
Study 1409765 — intervention group
Group type: COMPARATOR
Intervention: Harpagophytum procumbens (Devil's Claw) - 4 capsules of 500 mg powder containing 3% total glucoiridoids daily for 21 days
Number of subjects: 25
Study 2417351 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (low molecular weight heparinoid)
Number of subjects: 55
Study 2417351 — intervention group
Group type: COMPARATOR
Intervention: Heparin (loading dose 2,500 IU + continuous infusion of 1,800 IU/hr)
Number of subjects: 55
Study 2417351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Org 10172 and Heparin
Number of subjects: 55
Study 2417351 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 55
Study 2417351 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172
Number of subjects: 55
Study 30937736 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-based behavior analytic interventions delivered via telehealth over 12 weeks
Number of subjects: 10
Study 30937736 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent procedural integrity and acceptability ratings
Number of subjects: 10
Study 30324927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 44
Study 30324927 — intervention group
Group type: COMPARATOR
Intervention: Oral dexmedetomidine
Number of subjects: 44
Study 26398884 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans assessed by 9 blinded reviewers
Number of subjects: 100
Study 26398884 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus group discussion of CT scans
Number of subjects: 100
Study 26398884 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group reassessment of CT scans after consensus group recommendations
Number of subjects: 100
Study 26398884 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination vs consensus group assessment of CT scans
Number of subjects: 100
Study 25105662 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300mg)
Number of subjects: 14
Study 25105662 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (10mg)
Number of subjects: 14
Study 25105662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22238392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 182
Study 22238392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 20304883 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) cardiac troponin I testing
Number of subjects: 80
Study 20304883 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory testing
Number of subjects: 80
Study 17661940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity 2-octyl cyanoacrylate (HVOCA)
Number of subjects: 14
Study 17661940 — intervention group
Group type: COMPARATOR
Intervention: 5-0 polypropylene suture
Number of subjects: 14
Study 17661940 — intervention group
Group type: EXPERIMENTAL
Intervention: HVOCA
Number of subjects: 14
Study 16036196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (group A)
Number of subjects: 164
Study 16036196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 164
Study 12235926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dai-kenchu-to (DKT) 15 g orally daily for 14 days
Number of subjects: 24
Study 12235926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10404578 — intervention group
Group type: EXPERIMENTAL
Intervention: Active capacitively coupled electrical stimulation
Number of subjects: 179
Study 10404578 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 179
Study 8665534 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (100-800 mg)
Number of subjects: 12
Study 8665534 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg)
Number of subjects: 12
Study 8665534 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg and 800 mg)
Number of subjects: 12
Study 8665534 — intervention group
Group type: COMPARATOR
Intervention: CR levodopa-carbidopa without entacapone (control treatment)
Number of subjects: 12
Study 1837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep freezing with D.M.S.O. and staged decrease of temperature with immersion into liquid nitrogen
Number of subjects: 154
Study 1837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion into nitrogen without cryoprotection
Number of subjects: 154
Study 1837161 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep freezing in an electric device down to -80 degrees C
Number of subjects: 154
Study 1837161 — intervention group
Group type: COMPARATOR
Intervention: Fresh state (standard sample manufacturing)
Number of subjects: 154
Study 6355798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertransfusion (red cell transfusion to a hemoglobin value ≥ 17 gm/dl prior to each chemotherapy cycle)
Number of subjects: 25
Study 6355798 — intervention group
Group type: COMPARATOR
Intervention: Control (no hypertransfusion)
Number of subjects: 25
Study 30577901 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Line (RL) + Treatment-as-Usual (TAU)
Number of subjects: 82
Study 30577901 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 82
Study 29929861 — intervention group
Group type: EXPERIMENTAL
Intervention: ypT0 carcinoma
Number of subjects: 776
Study 29929861 — intervention group
Group type: EXPERIMENTAL
Intervention: ypT1 carcinoma
Number of subjects: 776
Study 29929861 — intervention group
Group type: EXPERIMENTAL
Intervention: ypT2 carcinoma
Number of subjects: 776
Study 29929861 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced ypT category
Number of subjects: 776
Study 29929861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic invasion
Number of subjects: 776
Study 29929861 — intervention group
Group type: EXPERIMENTAL
Intervention: RTD ≥10 mm
Number of subjects: 776
Study 26724671 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose X-ray examination (3.06 μSv)
Number of subjects: 264
Study 26724671 — intervention group
Group type: COMPARATOR
Intervention: Standard dose X-ray examination (4.57 μSv)
Number of subjects: 264
Study 26724671 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of defined criteria (dose-independent)
Number of subjects: 264
Study 24157241 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a helmet
Number of subjects: 19
Study 24157241 — intervention group
Group type: COMPARATOR
Intervention: No helmet
Number of subjects: 19
Study 21994078 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic procedure
Number of subjects: 13